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ABSTRACT
Objective To determine whether transdermal compared
withoraluseofhormonereplacementtherapyreducesthe
risk of gallbladder disease in postmenopausal women.
Design Prospective cohort study (Million Women Study).
Setting Women registered with the National Health
Service (NHS) in England and Scotland.
Participants 1001391 postmenopausal women (mean
age 56) recruited between 1996 and 2001 from NHS
breastscreeningcentresandfollowedbyrecordlinkageto
routinely collected NHS hospital admission data for
gallbladder disease.
Main outcome measures Adjusted relative risk and
standardised incidence rates of hospital admission for
gallbladder disease or cholecystectomy according to use
of hormone replacement therapy.
ResultsDuringfollow-up19889womenwereadmittedfor
gallbladder disease; 17190 (86%) had a
cholecystectomy. Compared with never usersof hormone
replacementtherapy,current usersweremorelikelytobe
admitted for gallbladder disease (relative risk 1.64, 95%
confidence interval 1.58 to 1.69) but risks were
substantially lower with transdermal therapy than with
oraltherapy(relativerisk1.17,1.10to1.24v1.74,1.68to
1.80; heterogeneity P<0.001). Among women using oral
therapy, equine oestrogens were associated with a
slightly greater risk of gallbladder disease than estradiol
(relative risk 1.79, 1.72 to 1.87 v 1.62, 1.54 to 1.70;
heterogeneity P<0.001) and higher doses of oestrogen
increased the risk more than lower doses: for equine
oestrogens >0.625 mg, 1.91 (1.78 to 2.04) v ≤0.625 mg,
1.76 (1.68 to 1.84); heterogeneity P=0.02; estradiol
>1 mg, 1.68 (1.59 to 1.77) v ≤1 mg, 1.44 (1.31 to 1.59);
heterogeneity P=0.003. The risk of gallbladder disease
decreased with time since stopping therapy (trend
P=0.004).Resultsweresimilartakingcholecystectomyas
the outcome. Standardised hospital admission rates per
100womenoverfiveyearsforcholecystectomywere1.1in
never users, 1.3 with transdermal therapy, and 2.0 with
oral therapy.
Conclusion Gallbladder disease is common in
postmenopausal women and use of hormone
replacement therapy increases the risk. Use of
transdermal therapy rather than oral therapy over a five
yearperiodcouldavoidonecholecystectomyinevery140
users.
INTRODUCTION
Randomised controlled trials and observational stu-
dies have shown a clear increase in the risk of
gallbladder disease (cholelithiasis, cholecystitis, or
cholecystectomy as outcomes) with use of hormone
replacement therapy by postmenopausal women.
1-4
Oestrogen administered orally is metabolised by the
liverbeforeenteringthesystemiccirculation(“firstpass
metabolism”). Oestrogen administered transdermally
avoids this first pass metabolism and it has been
suggested that it might have a lesser effect on
gallbladder disease than orally administered
oestrogen.
1 Hence we examined the relation between
method of administration and type of hormone
replacement therapy and the incidence of gallbladder
disease in a large cohort of postmenopausal women in
the United Kingdom.
METHODS
The Million Women Study is a population based
prospective study that recruited 1.3 million women,
aged 50-69 (mean age 56), from National Health
Service (NHS) breast screening clinics in England and
Scotlandduring1996-2001.Atrecruitmentthewomen
provided information on their use of hormone
replacement therapy, sociodemographic and anthro-
pometric factors, and medical and reproductive
history. Additional information, including repeat
questions on hormone replacement therapy and
questions on diet, was obtained at resurvey about
threeyearsafterrecruitment.Studyquestionnairescan
be viewed at www.millionwomenstudy.org.uk. Parti-
cipants provided written consent for inclusion and
follow-up.
All participants were registered with the NHS at
recruitment and their NHS number is a unique
personal identifier used in all NHS health records,
Epidemiology Unit, University of
Oxford, Oxford OX3 7LF
Correspondence to: B Liu
Bette.Liu@ceu.ox.ac.uk
Cite this as: BMJ 2008;337:a386
doi:10.1136/bmj.a386
BMJ | ONLINE FIRST | bmj.com page 1 of 9includingtheNHSbreastcancerscreeningprogramme
and admissions to NHS hospitals. Study participants
were followed by record linkage using their unique
NHS number and other personal details for deaths,
5
cancer registrations,
5 emigration,
5 and hospital
admissions,
67 thus providing close to complete fol-
low-upforalltheseevents.Thehospitaladmissiondata
include details of all NHS funded hospital admissions,
including day surgery, dating from 1981 in Scotland
6
and from 1997 in England.
7 For every hospital record
the primary reason for admission and up to 13
additional clinical diagnoses are coded using the
International Classification of Diseases 10th revision
(ICD-10)
8; as well, up to 12 procedures are coded
using the Office of Population Censuses and Surveys
Classification of SurgicalOperationsandProcedures,fourth
revision (OPCS 4).
9 For these analyses the main
outcome, gallbladder disease, is defined as the first
hospitaladmissionafterrecruitmenttothestudywitha
primarydiagnosisofcholelithiasisorcholecystitis(K80
and K81, ICD-10) or a cholecystectomy (codes J181-
J189, OPCS 4). Analyses were also done using as an
outcomethefirstadmissionforcholecystectomyalone
(codes J181-J189).
Statistical analysis
We excluded women from analyses if they were
premenopausal or perimenopausal (as previously
defined
10), had a history of cancer at baseline (except
non-melanomaskincancers;codeC44,ICD-10),hada
record of a hospital admission for gallbladder disease
before recruitment, or whose hormone replacement
therapy use was unknown. Person years were calcu-
lated from the date of recruitment to the date of first
hospital admission for gallbladder disease, date of
death, date of emigration, or the end of follow-up,
whichevercamefirst.ForwomenrecruitedinScotland
the last date of follow-up was 31 December 2003 and
for those in England the last date was 31 March 2005,
corresponding to the dates that the hospital records
were complete at the time of record linkage. We
calculatedpersonyearsfrom1April1997forthesmall
proportionofwomen(5%)recruitedinEnglandbefore
thatdate,ashospitaladmissiondatawerenotavailable
before then. Sensitivity analyses were done by
recalculating person years as in the main analysis but
censoring women who had breast cancer (C50, ICD-
10),cardiovasculardisease(I20-I25,I60-I69, ICD-10),
or thromboembolic disease (I26, I80-I82, ICD-10) at
thedateofdiagnosisoradmissiontohospitalforanyof
these events and also by censoring follow-up from 1
July 2002. In the sensitivity analyses we also excluded
women recruited in England before the date that
hospitaladmissionswereavailable(5%)andthosewho
reported pre-existing heart disease, stroke, or throm-
bosis at recruitment.
We used Cox regression to estimate the relative risk
ofhospitaladmissionforgallbladderdiseaseinrelation
touseofhormonereplacementtherapy.Analyseswere
routinely adjusted for area of recruitment (10 geogra-
phical regions), socioeconomic status in thirds (as
defined previously
10), body mass index (<22.5, 22.5-
24.9, 25-27.4, 27.5-29.9, 30-34.9, ≥35 kg/m
2), and
parity(nulliparous,parous),androutinelystratifiedfor
age(twoyearagecategories)andforhysterectomy(no,
yes), as hysterectomy is known to alter the type of
hormone replacement therapy prescribed. We also
examined the effect of adjusting for other potential
confounders including smoking,
11 alcohol intake,
12
physical activity,
13 dietary factors (intake of fruit,
vegetables, nuts, and coffee),
1415 previous oral contra-
ceptiveuse,
16treatmentforhypertension,
4reportingof
high cholesterol levels, and a history of stroke, heart
disease, thrombosis, or bilateral oophorectomy.
We categorised participants according to their
reported use of hormone replacement therapy at
recruitment. Proprietary hormone replacement ther-
apypreparationswereclassifiedonthebasisofmethod
of administration and hormonal constituents using the
British National Formulary.
17 We defined women as
users of oral therapy if they were taking any tablet
formulation of hormone replacement therapy or users
oftransdermaltherapyiftheywereusingapatchorgel
formulationofoestrogenwithorwithoutaprogestogen
(patch or tablet form). Women using oestrogen
implants were categorised separately. When the type
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Fig1 | Relativeriskofhospitaladmissionforgallbladderdiseasebyhormonereplacementtherapy
useatrecruitment.Dottedlinerepresentsoverallrelativeriskforpastuserscomparedwithnever
users. *Mean years of use estimated for cases at time of admission in current users and at
recruitment for past users, using resurvey information. †Relative risk compared to never users
stratified by age and hysterectomy and adjusted for region, socioeconomic group, body mass
index, and parity. Numbers for categoriesoftimesince last use donotsumtototal forpastusers
owing to missing values
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Fig 2 | Relative risk of hospital admission for gallbladder disease in current users of hormone
replacement therapy compared with never users by method of administration. Dotted line
representsoverallrelativeriskforallcurrentuserscomparedwithneverusers.*Meanyearsofuse
estimated for cases at time of admission for gallbladder disease, using resurvey information.
†Relative risk compared with never users stratified by age and hysterectomy and adjusted for
region, socioeconomic group, body mass index, and parity
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categorised, we included women in the “other and
unknown” category and included them in all analyses.
For past users of hormone replacement therapy we
assumed the time since last use increased by one year
for each year of follow-up. Furthermore, as hormone
usemayhavechangedduringfollow-up,weexamined
the potential effect of this by using information on use
ofhormonereplacementtherapyreportedatresurvey.
We calculated standardised incidence rates for
hospital admissions for cholecystectomy in users of
hormone replacement therapy, taking incidence rates
in never users as the standard and adjusting for age,
hysterectomy, region, socioeconomic group, body
mass index, and parity. Relative risks are reported
with 95% confidence intervals. Analyses were done
using Stata 9.2 statistical software.
RESULTS
Overall, 1001391 women were included in the
analyses, representing 95% of all women in the cohort
whowerepostmenopausalatrecruitment.Intotal,32%
were current users of hormone replacement therapy
and 18% were past users. Among current users, 77%
used an oral formulation, 18% a transdermal formula-
tion, and 5% other or unknown types. Table 1 shows
the baseline characteristics of participants by use of
hormone replacement therapy. Past and current users
differed primarily from never users as they were more
likelytohaveusedoralcontraceptivesandtohavehad
a hysterectomy or bilateral oophorectomy. Current
usersoftransdermalandoralformulationsweresimilar
for most characteristics except that hysterectomy and
bilateraloophorectomyweremorecommoninwomen
using transdermal therapy. On the basis of resurvey
data collected a mean of 2.8 years after recruitment
from 65% of participants, few women who were never
usersorpastusersatrecruitmentbecamecurrentusers
subsequently (1% and 3% per year, respectively). The
proportion of current users who stopped use after
recruitment was similar for users of oral therapy and
transdermal therapy (10% and 9% per year, respec-
tively). Among current users at recruitment who were
stillcurrentusersatresurvey,1%peryearwhoinitially
usedoraltherapyhadchangedtotransdermaltherapy,
whereas 4% per year who used transdermal therapy
had changed to oral therapy.
Participants were followed for 6102811 person
years (mean 6.1, interquartile range 5.4-7.0 years per
woman). During follow-up 19889 women had a first
admission for gallbladder disease, 17190 (86%) of
whom had a cholecystectomy. Admissions for gall-
bladder disease occurred a mean of 3.3 years after
recruitment.
Figure 1 shows the relation between the risk of
gallbladder disease and use of hormone replacement
therapy. Compared with never users, current and past
users had an increased risk of gallbladder disease,
although the risk was significantly greater in current
users (relative risk 1.64, 95% confidence interval 1.58
to 1.69) than in past users (1.27, 1.22 to 1.32; test for
heterogeneity χ
2
1=158, P<0.001). Among past users
the risk ofgallbladderdisease declinedwith increasing
time since last use (P=0.004 for linear trend); for
women whostopped hormoneuse more than 10 years
previously, however, the risk remained significantly
greater than in never users (1.19, 1.10 to 1.29). Results
were similar when cholecystectomy was taken as the
outcome: on the basis of 6406 cholecystectomies in
never users, 7570 in current users, and 3214 in past
users,therelativeriskforcurrentuserswas1.69(1.63to
1.75) and for past users was 1.29 (1.23 to 1.34).
Figure 2 shows results by the method of hormone
administration.Currentusersoforal,transdermal,and
Table 1 |Characteristicsofparticipantsandfollow-upforgallbladderdiseaseaccordingtohormonereplacementtherapyuseat
recruitment.Valuesarepercentages(number)unlessstatedotherwise
Characteristic Never users Past users
Method of administration in current users
Oral Transdermal Other or unknown*
No of women 478 180 181 857 263 871 60 247 17 236
Mean (SD) age (years) 58.2 (4.4) 57.5 (4.0) 56.5 (3.9) 56.4 (3.9) 56.1 (4.1)
Mean (SD) body mass index (kg/m
2) 26.5 (4.9) 26.5 (4.6) 25.6 (4.3) 26.1 (4.3) 26.0 (4.4)
Upper third socioeconomic group 31.6 (149 877) 33.4 (60 195) 34.8 (91 035) 36.0 (21 490) 34.8 (5938)
Current smoker 20.2 (90 383) 20.9 (35 804) 20.8 (51 891) 19.0 (10 813) 20.2 (3249)
Mean (SD) alcohol intake (g/day) 5.3 (7.1) 6.2 (7.5) 6.8 (7.8) 6.8 (7.8) 6.6 (7.8)
Mean (SD) parity 2.2 (1.3) 2.2 (1.2) 2.1 (1.2) 2.2 (1.2) 2.2 (1.2)
Ever used oral contraceptives 46.3 (219 306) 60.8 (109 371) 64.4 (168 154) 61.8 (36 775) 65.4 (11 123)
Treated for hypertension 18.0 (85 834) 17.0 (30 930) 17.0 (44 762) 17.5 (10 506) 16.4 (2826)
Reporting high cholesterol level 12.7 (60 691) 13.7 (24 937) 11.0 (28 981) 14.1 (8465) 10.7 (1845)
Heart disease, stroke, or thrombosis 11.0 (52 416) 11.3 (20 513) 8.2 (21 416) 10.9 (6540) 9.8 (1696)
Hysterectomy 14.8 (70 213) 27.1 (48 875) 32.6 (85 521) 73.5 (44 168) 65.9 (11 301)
Bilateral oophorectomy 3.1 (14 024) 10.0 (17 286) 15.2 (38 040) 36.8 (20 613) 44.9 (7292)
Person years of follow-up 2 926 227 1 095 950 1 609 704 365 590 105 340
No admitted with gallbladder disease 7581 3708 6914 1249 437
Percentages calculated excluding women with missing values.
*Includes women using oestrogen implants.
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diseasethanneverusersbuttherisksweresignificantly
different depending on the method of administration
(heterogeneity χ
2
3=170, P<0.001). Transdermal
therapy conferred a substantially lower risk of gall-
bladder disease than oral therapy (relative risk 1.17,
1.10to1.24v1.74,1.68to1.80;heterogeneityχ
2
1=166,
P<0.001). The lower risk with transdermal therapy
All women
Age (years)
  <55
  >55
Body mass index (kg/m2)
  <25
  25-29.9
  30-34.9
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Fig 3 | Relative risk of hospital admission for gallbladder disease in current users of oral and transdermal hormone replacement
therapy compared with never users in various subgroups. Dotted lines represent overall relative risk for all users of oral therapy
comparedwithneverusersand allusers oftransdermaltherapycomparedwithnever users,respectively.*Relative risk compared
withneverusers stratifiedbyage and hysterectomyand,whenappropriate,adjustedfor region, socioeconomicgroup,bodymass
index, and parity
RESEARCH
page 4 of 9 BMJ | ONLINE FIRST | bmj.comcompared with oral therapy was also seen when
cholecystectomy alone was used as the outcome:
relative risk 1.18 (1.10 to 1.27) and 1.80 (1.74 to
1.87), respectively.
Relative risks did not change substantially when
simultaneous adjustment was made for the additional
potential confounders of smoking status, alcohol
intake, physical activity, previous oral contraceptive
use, treatment for hypertension, reporting of high
cholesterollevels,dietaryfactors,andhistoryofstroke,
heart disease, thrombosis, or bilateral oophorectomy:
for transdermal therapy the relative risk changed from
1.17 to 1.21 and for oral therapy from 1.74 to 1.79.
The relative risk of gallbladder disease in current
users of oral and transdermal therapies was also
compared with never users in various subgroups of
womenthathadbeendefinedapriori(fig 3).
101819The
relative risks differed significantly only by body mass
index, decreasing with increasing body mass index:
relative risk was 1.88 (1.77 to 2.01) for a body mass
index<25kg/m
2and1.47(1.30to1.67)forabodymass
index ≥35 kg/m
2;P =0.001 for trend.
Figure4showsresultsforvariousfeaturesoftheoral
hormone replacement therapies. The risk of gallblad-
der disease was not significantly related to duration of
use but did vary significantly by type of oestrogen and
dose (fig 4). Women using equine oestrogens had a
significantly higher risk of gallbladder disease than
those using estradiol: relative risk 1.79 (1.72 to 1.87) v
1.62 (1.54 to 1.70); heterogeneity χ
2
1=13.7, P<0.001.
Furthermore, use of both equine oestrogen and
estradiol at higher doses were associated with greater
risks than lower doses: with equine oestrogen the
relativeriskswere1.76(1.68to1.84)for≤0.625mgand
1.91 (1.78 to 2.04) for >0.625 mg (heterogeneity
χ
2
1=5.2, P=0.02); with estradiol the risks were 1.44
(1.31 to 1.59) for ≤1 mg and 1.68 (1.59 to 1.77) for
>1mg(heterogeneityχ
2
1=8.6,P=0.003).Nosubstantial
variation was found in risk between users of oestrogen
only, oestrogen plus progestogen, tibolone, and other
types (heterogeneity χ
2
3=7.1, P=0.07). Within each
category of oestrogen type and dose, the type of
progestogen used and frequency of administration
varied considerably, limiting comparisons (table 2).
Sequential norgestrel is represented in each category
All oral preparations
Duration of use (years)
  <5
  5-9
  >10
Oestrogen constituent and dose
  All equine oestrogen
  Dose <0.625 mg
            >0.625 mg
  All estradiol
  Dose <1 mg
            >1 mg
Type
  Oestrogen only
  Oestrogen + progestogens
  Tibolone
  Other
1.74 (1.68 to 1.80)
1.76 (1.68 to 1.85)
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1.77 (1.67 to 1.86)
1.79 (1.72 to 1.87)
1.76 (1.68 to 1.84)
1.91 (1.78 to 2.04)
1.62 (1.54 to 1.70)
1.44 (1.31 to 1.59)
1.68 (1.59 to 1.77)
1.81 (1.72 to 1.92)
1.69 (1.62 to 1.76)
1.84 (1.69 to 2.00)
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Fig4 | Relativeriskofhospitaladmissionforgallbladderdiseaseincurrentusersoforalhormone
replacementtherapycomparedwithneverusersbydurationofuseandtypeoftherapyreportedat
recruitment.Dottedlinerepresentsoverallrelativeriskforallusersoforaltherapycomparedwith
neverusers.*Meanyearsofuseestimatedforcasesattimeofadmissionforgallbladderdisease,
using resurvey information. †Relative risk compared with never users stratified by age and
hysterectomy and adjusted for region, socioeconomic group, body mass index, and parity.
Numbers in subcategories do not necessarily sum to totals owing to missing values
Table 2 |Relativeriskofhospitaladmissionforgallbladderdiseaseincurrentusersoforalhormonereplacementtherapycompared
withneverusersbytypeofoestrogen,dose,andadditionofprogestogens*
Type and dose of
oestrogen Progestogen use
No of women with gallbladder
disease Relative risk (95%CI)
Equine oestrogen (mg):
≤0.625 None 1250 1.76 (1.64 to 1.87)
Norgestrel (sequential†) 981 1.69 (1.58 to 1.80)
Medroxyprogesterone (continuous‡) 674 1.92 (1.77 to 2.08)
>0.625 None 704 2.09 (1.93 to 2.28)
Norgestrel (sequential†) 311 1.66 (1.48 to 1.86)
Estradiol (mg):
≤1 None 253 1.55 (1.37 to 1.77)
Norgestrel (sequential†) 70 1.33 (1.05 to 1.69)
>1 None 275 1.79 (1.58 to 2.03)
Norgestrel (sequential†) 169 1.34 (1.15 to 1.56)
Norethisterone (sequential†) 305 1.54 (1.37 to 1.73)
Norethisterone (continuous‡) 755 1.80 (1.67 to 1.95)
*Progestogen types are listed where there were more than 50 women with gallbladder disease.
†Progestogens taken for 10-14 days of each monthly cycle for most women.
‡Progestogens taken daily.
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gallbladder disease than the other oral preparations;
the lack of information on the other progestogens,
however, makes these findings difficult to interpret.
Figure 5 shows results for various features of the
transdermal preparations. Estradiol was the only type
of oestrogen administered transdermally and no
significant differences were found by duration of its
use, dose, or whether it was used alone or with a
progestogen (fig 5). Progestogens administered orally
or transdermally did not appreciably alter the relative
risk associated with use of transdermal oestrogen.
Table 3 shows the main findings for hormone
replacement therapy and gallbladder disease com-
pared with results from the sensitivity analyses where
follow-upwascensoredandadditionalexclusionswere
applied to the cohort. Although the relative risk
estimates were marginally higher than in the main
analysistherelationbetweenneverusers,currentusers,
andpastusersofhormonereplacementtherapydidnot
change appreciably. Also, transdermal therapy con-
sistently conferred a lower risk of gallbladder disease
than oral therapy.
The standardised incidence rates per 100 women
over fiveyearsin neverusersofhormonereplacement
therapy were 1.3 (95% confidence interval 1.3 to 1.3)
for hospital admissions with gallbladder disease and
1.1 (1.1 to 1.1) for cholecystectomy alone. The
corresponding rates for current users of transdermal
therapywere1.5(1.4to1.6)and1.3(1.2to1.4)andfor
current users of oral therapy were 2.3 (2.2 to 2.3) and
2.0 (1.9 to 2.0). From these figures over five years the
absolutedifferenceinriskbetweencurrentusersoforal
therapy and transdermal therapy was 0.8 per 100
womenforgallbladderdiseaseand0.7per100women
for cholecystectomy. Hence among women using
transdermal therapy compared with oral therapy
over five years, one fewer admission for gallbladder
disease would be expected in every 125 women and
onefeweradmissionforcholecystectomy in every140
women.
DISCUSSION
Use of hormone replacement therapy by postmeno-
pausalwomenincreasestheriskofgallbladderdisease.
This finding agrees with previous reports.
1-4 We also
found a substantially lower risk of gallbladder disease
withuse of transdermal therapythanwith oral therapy
(relative risk 1.17 v 1.74). Oestrogens administered
orally are absorbed in the gut and travel through the
portal vein to the liver where they are extensively
metabolised through conjugation before entering the
systemic circulation. The metabolites are excreted
through the bile and urine.
20 Transdermal oestrogens
are administered in lower doses than oral oestrogens
andareabsorbedthroughtheskinanddirectlyintothe
circulation. By avoiding first pass metabolism there
shouldbelowerconcentrationsofoestrogensandtheir
metabolites in the bile and this may well explain the
lowerriskofgallbladderdiseasethatwe observedwith
transdermal therapy.
Among users of oral hormone therapy we found a
dose effect, with increased relative risks of gallbladder
disease among users of higher doses compared with
lowerdoses.Thesefindingssuggestthattheconcentra-
tion of oestrogen and its metabolites in the bile affect
theriskofgallbladderdisease.Useofequineoestrogen
wasassociatedwithaslightlyhigherriskofgallbladder
disease than estradiol and this may be because the
equine preparations consist largely of conjugated
oestrogens, which are metabolised somewhat differ-
ently from estradiol
20; however, it is unknown what
effects this may have on biliary concentrations of
hormone.Oestrogenimplants,whichcanresultinhigh
blood concentrations of oestrogen
20-22 but avoid the
first pass metabolism, were also found to increase the
relativeriskofgallbladderdiseasetoalevelsomewhere
between oral users and transdermal users.
Ourresultssuggestthattheadditionofprogestogens
to oestrogen therapy does not have a large additional
effect on the risk of gallbladder disease. This is in
agreement with findings from the women’s health
initiative randomised controlled trial.
1 Furthermore,
among users of transdermal oestrogens, the risks did
notvaryappreciablyiftheprogestogenswereadminis-
tered orally or transdermally, although owing to the
number of cases statistical power was limited.
In past users of hormone replacement therapy the
risk of gallbladder disease was lower than in current
users and decreased gradually with increasing time
since therapy stopped although some excess risk still
All transdermal oestrogens
Duration of use (years)
  <5
  5-9
  >10
Type
  Estradiol only
  Estradiol + transdermal
  Estradiol + oral progestogen
Estradiol dose (micrograms)
  <50
  >50
progestogen
1.17 (1.10 to 1.24)
1.11 (0.99 to 1.24)
1.19 (1.09 to 1.30)
1.18 (1.05 to 1.33)
1.17 (1.09 to 1.26)
1.20 (1.01 to 1.43)
1.28 (0.99 to 1.64)
1.15 (1.07 to 1.23)
1.25 (1.11 to 1.40)
0123
7.2
4.1
7.2
11.3
7.4
6.0
7.3
7.1
7.4
Duration of
use (years)*
1249/60 247
359/18 638
545/25 668
308/14 477
1057/48 455
130/8301
62/3491
947/47 399
302/12 848
Cases/
population
Relative risk
(95% CI)†
Relative risk
(95% CI)†
Fig 5 | Relative risk of hospital admission for gallbladder disease in current users of transdermal
hormone replacement therapy comparedwith never users by durationof use andtype of therapy
reported at recruitment. Dotted line represents overall relative risk for all users of transdermal
therapycomparedwithneverusers.*Meanyearsofuseestimatedforcasesattimeofadmission
for gallbladder disease, using resurvey information. †Relative risk compared with never users
stratified by age and hysterectomy and adjusted for region, socioeconomic group, body mass
index, and parity. Numbers in subcategories do not necessarily sum to totals owing to missing
values
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that oestrogen induces some persistent change in the
gallbladder. Similar findings have been described in
other studies
323 and one possible explanation is the
formationof asymptomatic gallstones,which continue
to increase a woman’s risk of gallbladder disease long
afterstoppinghormonereplacementtherapy.
23Results
from one study suggest that the risk of gallbladder
disease may increase with increasing duration of use
3;
howeverwefoundnosignificanttrends.Finally,wedid
not compare the risks associated with past use of oral
and transdermal formulations because a large propor-
tion of past users provided no information on the type
of hormone replacement therapy used and evidence
suggests that recall of brand names by past users is
poor.
24
Among users of oral hormone replacement therapy
therelativerisk,butnottheabsoluterisk,ofgallbladder
disease associated with hormone replacement therapy
was found to decrease with increasing body mass
index. A similar attenuation of the hormone replace-
ment therapy associated relative risks in overweight
and obese women has been observed with breast
cancer
25andendometrialcancer.
18Theabsoluteriskof
gallbladder disease increases with increasing body
mass index
26 probably because circulating levels of
endogenous oestradiol are higher in overweight and
obese women and the addition of exogenous oestro-
gens may alter total oestrogen levels to a lesser extent
thaninthinnerwomen(seefig3).Ithasbeensuggested
that the attenuated relative risks with increasing body
mass index might be because we could not exclude
every woman who had a cholecystectomy before
recruitment, although additional analyses suggest this
is unlikely.
Strengths and limitations
Our results are based on hormone replacement
therapy use reported at recruitment and although
some changes in use occurred during follow-up this
would not substantially alter our findings. Admissions
for gallbladder disease occurred a mean of 3.3 years
after recruitment and, on the basis of resurvey data, a
small proportion of never users, only 1% annually,
starteduseafterrecruitment.Theproportionofcurrent
users stopping therapy was similar for women using
oral and transdermal preparations and few women
switched between oral and transdermal therapies.
Sensitivity analyses showed that our estimates of
relativeriskwereessentiallyunchangedaftercensoring
women at major events that may alter the use of
hormone replacement therapy. Also, after censoring
follow-up at July 2002 (to coincide with publication of
the first results from the women’s health initiative
trials
27), significant differences between the effect of
transdermal therapy and oral therapy persisted.
In this cohort, the findings relating to the method of
administration of hormone replacement therapy are
specific for gallbladder disease, as we found no
differences between transdermal therapy and oral
therapy for increased risk of breast cancer
10 and
ovarian cancer,
19 or the reduced risk of fracture.
28
Prescribing of transdermal oestrogen rather than oral
oestrogen differs according to some factors such as
history of hysterectomy and bilateral oophorectomy
(seetable 1)butwewereabletoadjustfortheseaswell
asotherpotentialconfoundersthatcouldinfluencethe
choice of hormone replacement therapy such as
socioeconomic status, body mass index, and other
medical history.
Although some non-NHS funded admissions would
not be included in our follow-up, privately funded
treatment in the United Kingdom is limited,
29 and we
have previously shown that in this cohort such
admissions are uncommon, as most self reported
cholecystectomies were included in our linked NHS
hospital admission data.
30 We excluded from the
analyses women with a record of admission for
gallbladder disease before recruitment as most of
these women will have had a cholecystectomy and
would no longer be at risk of an event. For women
recruited in Scotland, hospital records were available
from 1981 (when participants were a mean age of 36).
In these women, had we not excluded those with an
admission before recruitment, the relative risks for
gallbladder disease in current users of hormone
Table 3 |Sensitivityanalysesofriskofhospitaladmissionforgallbladderdiseaseaccordingtohormonereplacementtherapy(HRT)
use.Valuesarerelativerisks(95%confidenceintervals)unlessstatedotherwise
Main model
Follow-up censored at
diagnosis or admission for
medical illness*
Follow-up censored at diagnosis
or admission for medical
illness* or on July 2002
No of women 1 001 391 857 503 857 503
Mean person years of follow-up 6.1 5.8 3.4
No admitted to hospital for gallbladder
disease
19 889 15 248 8330
HRT use compared with never users: —— —
All current users 1.64 (1.58 to 1.69) 1.69 (1.62 to 1.75) 1.82 (1.72 to 1.91)
All past users 1.27 (1.22 to 1.32) 1.31 (1.25 to 1.37) 1.34 (1.26 to 1.43)
Current users of oral HRT 1.74 (1.68 to 1.80) 1.79 (1.72 to 1.86) 1.94 (1.84 to 2.05)
Current users of transdermal HRT 1.17 (1.10 to 1.24) 1.21 (1.12 to 1.30) 1.20 (1.09 to 1.32)
*In all sensitivity analyses women who were recruited in England before hospital admission data were available and those who reported pre-existing
heart disease, stroke, or thrombosis were excluded. Follow-up was censored if the participant had breast cancer, cardiovascular disease, or
thromboembolic disease at date of diagnosis or admission to hospital.
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1.70 instead of 1.71, and the relative risks for
transdermal therapy versus oral therapy would have
been 1.13 versus 1.83 instead of 1.13 versus 1.85. For
women recruited in England, hospital records were
available only from 1997; however, the small differ-
ence in relative risks in Scotland suggests that not
excluding comparable women in England would have
a minimal effect on our estimates.
Despite these limitations, the study has several
strengths. All women were registered with the NHS,
and by linking to NHS hospital records we had
virtually complete follow-up, with objective recording
ofgallbladderdisease.Thelargesamplesizeallowedus
to compare reliably a variety of types of hormone
replacement therapy. The prospective design ensured
that use of hormone replacement therapy was ascer-
tained before outcomes thereby reducing biases
resulting from recall or differential prescribing, and
we were able to adjust for many potential confounders
and found our results to be consistent. Reporting of
hormone replacement therapy use in this population
compares well with prescription data,
31 and outcomes
were coded by the NHS hospitals, independent of the
studyinvestigatorsandparticipants.Additionally,both
the accuracy of the linkage process and the coding of
gallbladder disease has been shown to be good
630and
as misclassification of hormone replacement therapy
use at recruitment or of gallbladder disease from the
hospital records should be non-differential, this would
result in an underestimate of the effects found.
Implications for practice
Gallbladder disease is common in middle aged
women. In the UK over five years an estimated 1.1%
ofmiddleagedwomenwhohaveneverusedhormone
replacement therapy are admitted to hospital for a
cholecystectomy. Use of transdermal oestrogen
increases the risk to 1.3% and use of oral oestrogens
increases this to 2.0%. Transdermal hormone replace-
ment therapy is, however, generally more costly than
oral therapy and can cause local skin reactions.
2021
Whereas the number of women using hormone
replacement therapy halved between 2002 and 2005,
about 1 million UK women were taking it in 2005 and
mostusedoralpreparations.
32Forwomenwhochoose
to use hormone replacement therapy, one cholecys-
tectomy could be avoided for every 140 users of
transdermal therapy rather than oral therapy over a
five year period.
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